ArticleParasites & vectors2025
Enzymes involved in trehalose-chitin synthesis in Haemonchus contortus could be vaccine candidates for goats.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTrehalose-6-phosphate synthase (HcTPS) and trehalose-6-phosphate phosphatase (HcGOB) are key enzymes for trehalose synthesis in Haemonchus contortus. In addition, previous studies have also demonstrated that HcTPS and HcGOB can regulate the function of host immune cells in vitro, and are important immunosuppressive molecules. Therefore, this study evaluated the potential of HcTPS and HcGOB as vaccine candidates through in vitro and in vivo experiments.
methodsTo evaluate the inhibitory effects of polyclonal antibodies on egg hatching and larval development, anti-rHcTPS and anti-rHcGOB antibodies were incubated separately with eggs and first-stage larvae (L1s) under controlled in vitro conditions. For immunization studies, recombinant proteins (rHcTPS and rHcGOB) were formulated with Quil-A adjuvant, and administered to goats through subcutaneous injection. Vaccine efficacy against Haemonchus contortus infection was determined through comprehensive analysis of multiple parasitological parameters, including: (1) egg abnormality rate, (2) hatching success rate, (3) reduction egg output rates, and (4) reduction in adult worm burden.
resultsThe results of in vitro experiments showed that polyclonal antibodies against HcTPS and HcGOB had no effect on the hatching rate of eggs, but significantly affected the development from L1s to infectious third stage larvae (L3s). After immunization with recombinant HcTPS protein (rHcTPS) and recombinant HcGOB protein (rHcGOB), high levels of antigen-specific immunoglobulin G (IgG) were produced in goats, and remained till the end of the experiment. Compared with the Quil-A adjuvant control group, the number of deformed eggs in the rHcTPS protein- immunized group and the rHcGOB protein- immunized group were significantly increased. In the rHcTPS protein-immunized group and the rHcGOB protein-immunized group, the deformity rate of eggs was 9.59% and 17.30%, respectively, and the hatching rate of eggs was reduced by 11.27% and 13.71%, respectively. Moreover, compared with the Quil-A adjuvant control group, the number of eggs and adults in the HcTPS protein- immunized group decreased by 64.47% and 60.93%, respectively, and the number of eggs and adults in the rHcGOB protein- immunized group decreased by 63.97% and 69.54%, respectively. Furthermore, compared with the control group (Quil-A adjuvant), the trehalose content in the rHcTPS protein- immunized group and the rHcGOB protein- immunized group was also significantly reduced.
conclusionsThese findings indicate that rHcTPS and rHcGOB exhibit superior immune protective effects, rendering them promising candidates for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.